Background: Combined MET and BRAF inhibition showed clinical benefit in a patient with rectal cancer carrying BRAFV600E and MET amplification. However after 4 months, acquired resistance emerged and the patient deceased shortly after disease progression. The mechanism of resistance to this drug combination is unknown. Methods: We analysed plasma circulating tumour DNA obtained at progression by exome sequencing and digital PCR. MET gene and mRNA in situ hybridisation analyses in two bioptic specimens obtained at progression were used to confirm the plasma data. Results: We identified in plasma MET gene hyper-amplification as a potential mechanism underlying therapy resistance. Increased MET gene copy and transcript levels were detected in liver and lymph node metastatic biopsies. Finally, transduction of MET in BRAF mutant colorectal cancer cells conferred refractoriness to BRAF and MET inhibition. Conclusions: We identified in a rectal cancer patient MET gene hyper-amplification as mechanism of resistance to dual BRAF and MET inhibition.

Emergence of MET hyper-amplification at progression to MET and BRAF inhibition in colorectal cancer

Oddo D;Siravegna G;Crisafulli G;Buscarino M;Rospo G;Lamba S;Bardelli A;Di Nicolantonio F.
Co-last
2017

Abstract

Background: Combined MET and BRAF inhibition showed clinical benefit in a patient with rectal cancer carrying BRAFV600E and MET amplification. However after 4 months, acquired resistance emerged and the patient deceased shortly after disease progression. The mechanism of resistance to this drug combination is unknown. Methods: We analysed plasma circulating tumour DNA obtained at progression by exome sequencing and digital PCR. MET gene and mRNA in situ hybridisation analyses in two bioptic specimens obtained at progression were used to confirm the plasma data. Results: We identified in plasma MET gene hyper-amplification as a potential mechanism underlying therapy resistance. Increased MET gene copy and transcript levels were detected in liver and lymph node metastatic biopsies. Finally, transduction of MET in BRAF mutant colorectal cancer cells conferred refractoriness to BRAF and MET inhibition. Conclusions: We identified in a rectal cancer patient MET gene hyper-amplification as mechanism of resistance to dual BRAF and MET inhibition.
117
3
347
352
https://www.nature.com/bjc/journal/v117/n3/full/bjc2017196a.html
BRAF; colorectal cancer; crizotinib; drug resistance; target therapy; MET
Oddo, D; Siravegna, G; Gloghini, A; Vernieri, C; Mussolin, B; Morano, F; Crisafulli, G; Berenato, R; Corti, G; Volpi, Cc; Buscarino, M; Niger, M; Dunne, Pd; Rospo, G; Valtorta, E; Bartolini, A; Fucà, G; Lamba, S; Martinetti, A; Di Bartolomeo, M; de Braud, F; Bardelli, A; Pietrantonio, F; Di Nicolantonio, F.
File in questo prodotto:
File Dimensione Formato  
Oddo_BJC_2017_postprint_4aperto.pdf

Accesso aperto con embargo fino al 28/12/2017

Descrizione: Articolo principale e dati supplementari
Tipo di file: POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione 3.03 MB
Formato Adobe PDF
3.03 MB Adobe PDF Visualizza/Apri
2017_Oddo_BritJCancer_Article&SI.pdf

Accesso riservato

Descrizione: Articolo principale (PDF Editoriale) e dati supplementari
Tipo di file: PDF EDITORIALE
Dimensione 1.67 MB
Formato Adobe PDF
1.67 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2318/1647300
Citazioni
  • ???jsp.display-item.citation.pmc??? 12
  • Scopus 24
  • ???jsp.display-item.citation.isi??? 24
social impact